1. A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY. (21st February 2022) Authors: Panaccione, R; Ferrante, M; Feagan, B G; Sandborn, W; Panes, J; Peyrin-Biroulet, L; Colombel, J; Schreiber, S; Dubinsky, M; Baert, F; Hisamatsu, T; Neimark, E; Huang, B; Liao, X; Song, A; Berg, S; Duan, W; Pang, Y; Pivorunas, V; Kligys, K Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN'S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE. (15th March 2019) Authors: Panaccione, R; Colombel, J; Bossuyt, P; Baert, F; Vanasek, T; Danalioglu, A; Novacek, G; Armuzzi, A; Reinisch, W; Johnson, S; Buessing, M; Neimark, E; Petersson, J; Robinson, A M; Thakkar, R B; Lee, W; Skup, M; D'Haens, G Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 2(2019)Supplement 2 Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP065 Long-term cost-effectiveness of tight control for Crohn's disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial. (16th January 2018) Authors: Panaccione, R; Colombel, J -F; Bossuyt, P; Baert, F; Vanasek, T; Danalioglu, A; Novacek, G; Armuzzi, A; Reinisch, W; Johnson, S; Buessing, M; Neimark, E; Petersson, J; Robinson, A M; Thakkar, R B; Lee, W -J; Skup, M; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S074 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP071 Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn's disease: data from CALM. (16th January 2018) Authors: Panaccione, R; Colombel, J -F; Bossuyt, P; Baert, F; Vanasek, T; Danalioglu, A; Novacek, G; Armuzzi, A; Reinisch, W; Neimark, E; Petersson, J; Robinson, A M; Thakkar, R B; Chen, N; Skup, M; Lee, W -J; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S078 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohn's Disease during treatment with risankizumab. (21st January 2022) Authors: Schreiber, S W; Cross, R; Panaccione, R; D'Haens, G; Bossuyt, P; Colombel, J F; Louis, E; Dubinsky, M; Kligys, K; Neimark, E; Song, A; Zambrano, J; Cheng, E; Ferrante, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. (21st January 2022) Authors: Atreya, R; Feagan, B; Shchukina, O; Jairath, V; Rieder, F; Hisamatsu, T; Siegmund, B; Rizzo, J; Kligys, K; Neimark, E; Song, A; Zambrano, J; Mallick, M; Cheng, E; Armuzzi, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. DOP84 Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn's Disease: Post-hoc analysis from the phase 3 study FORTIFY. (21st January 2022) Authors: Irving, P M; Abreu, M; Axler, J; Gao, X; Torres, J; Neimark, E; Song, A; Wallace, K; Kligys, K; Berg, S; Liao, X; Panaccione, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DOP85 Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy. (21st January 2022) Authors: Baert, F J; Atreya, R; Kakuta, Y; Long, M; Roblin, X; Neimark, E; Song, A; Wallace, K; Kingys, K; Mallick, M; Liao, X; Lim, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OP25 Patients with moderate to severe Crohn's Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials. (21st January 2022) Authors: Ferrante, M; Cao, Q; Fujii, T; Rausch, A; Neimark, E; Song, A; Wallace, K; Kligys, K; Zhou, Q; Kalabic, J; Feagan, B G Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i027 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. (27th May 2021) Authors: Schreiber, S W; Ferrante, M; Panaccione, R; Colombel, J F; Hisamatsu, T; Lim, A; Lindsay, J O; Rubin, D T; Sandborn, W J; Neimark, E; Song, A P; Liao, X; Feng, T; Berg, S; Wallace, K; D'Haens, G R Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S026 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗